Association of steroid and xenobiotic receptor (SXR) and multidrug resistance 1 (MDR1) gene expression with survival among patients with invasive bladder carcinoma

BJU International

Volumn 107, Issue 11, 2011, Pages 1833-1838

  Rioja, Jorge ^a,d   Bandrés, Eva ^c   Rosell Costa, David ^a   Rincón, Anibal ^a   López, Ines ^c   Zudaire Bergera, Juan Javier ^a   García Foncillas, Jesús ^c   Gil, María Jesús ^c   Panizo, Angel ^b   Plaza, Luis ^d   Rioja, Luis Angel ^c   Berián Polo, José María ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

invasive bladder cancer; multidrug resistance 1 (MDR1); prognostic factors; steroid and xenobiotic receptor (SXR); survival

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; STEROID AND XENOBIOTIC RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; DISTANT METASTASIS; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION;

AGED; ANALYSIS OF VARIANCE; COHORT STUDIES; CYSTECTOMY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, STEROID; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 79956369333     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09653.x     Document Type: Article

References (24)

1. Stenzl A, Cowan NC, De Santis M, et al,. The updated EAU Guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009; 55: 815-25
2. Yu RJ, Stein JP, Cai J, Miranda G, Groshen S, Skinner DG,. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol 2006; 176: 493-9 (Pubitemid 43927925)
3. Stein JP, Quek ML, Skinner DG,. Lymphadenectomy for invasive bladder cancer. II. technical aspects and prognostic factors. BJU Int 2006; 97: 232-7
4. Wallerand H, Reiter RR, Ravaud A,. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways. Curr Opin Urol 2008; 18: 524-32
5. Rioja Zuazu J, Bandrés Elizalde E, Rosell Costa D, et al,. [Steroid and xenobiotic receptor (SXR), multidrug resistance gene (MDR1) and GSTs, SULTs and CYP polymorphism expression in invasive bladder cancer, analysis of their expression and correlation with other prognostic factors]. Actas Urol Esp 2007; 31: 1107-16
6. Blumberg B, Sabbagh W Jr, Juguilon H, et al,. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 1998; 12: 3195-205 (Pubitemid 28496264)
7. Blumberg B, Kang H, Bolado J Jr, et al,. BXR, an embryonic orphan nuclear receptor activated by a novel class of endogenous benzoate metabolites. Genes Dev 1998; 12: 1269-77 (Pubitemid 28213403)
8. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA,. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998; 102: 1016-23 (Pubitemid 28419246)
9. Bertilsson G, Heidrich J, Svensson K, et al,. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 1998; 95: 12208-13 (Pubitemid 28483744)
10. Geick A, Eichelbaum M, Burk O,. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001; 276: 14581-7
11. Willson TM, Kliewer SA,. PXR, CAR and drug metabolism. Nat Rev Drug Discov 2002; 1: 259-66 (Pubitemid 37361442)
12. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, Kliewer SA,. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 2002; 62: 638-46 (Pubitemid 36329382)
13. Zhou C, Tabb M, Sadatrafei A, Grun F, Blumberg B,. Tocotrienols activate the steroid and xenobiotic receptor, SXR, and selective regulate expresión of its target genes. Drug Metab Dispos 2004; 32: 1075-82 (Pubitemid 39287580)
14. Miki Y, Suzuki T, Tazawa C, Blumberg B, Sasano H,. Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Mol Cell Endocrinol 2005; 231: 75-85 (Pubitemid 40248818)
15. Oosterlinck W, Lobel B, Jackse G, Malmstrom PU, Stockle M, Strenberg C,. European Associations of Urology (EAU) Working Group on Oncological Urology. Guidelines on bladder cancer. Eur Urol 2002; 41: 105-12
16. Montie JE, Abrahams NA, Bahnson RR, et al,. Bladder cancer. Clinical guidelines in oncology. J Natl Compr Canc Netw 2006; 4: 984-1014 (Pubitemid 44845488)
17. Applied Biosystems. User Bulletina™®2. ABI Prism 7700 Sequence Detection System. 200I updated version. Available at:. Accessed July 2010
18. Lodde M, Fradet Y,. The detection of genetic markers of bladder cancer in urine and serum. Curr Opin Urol 2008; 18: 499-503
19. Vrooman OP, Witjes JA,. Urinary markers in bladder cancer. Eur Urol 2008; 53: 909-16
20. van Rhijn BW, van der Poel HG, van der Kwast TH,. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005; 47: 736-48 (Pubitemid 40745338)
21. Bellmunt J, Paz-Ares L, Cuello M, et al,. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007; 18: 522-8 (Pubitemid 46359633)
22. Chakravarti A, Winter K, Wu CL, et al,. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005; 62: 309-17 (Pubitemid 40704444)
23. Kaufman DS, Shipley WU, Feldman AS,. Bladder cancer. Lancet 2009; 374: 239-49
24. Alvarez Kindelán JA, López-Beltrán A, Requena Tapia MJ,. [Molecular biology in bladder cancer]. Actas Urol Esp 2000; 24: 604-25